EICHOR
● Active Not Recruiting
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Condition: Non-Small Cell Lung Cancer · Sponsor: EMD Serono Research & Development Institute, Inc.
About this study
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (54)
| UCLA Hematology and Oncology - Santa Monica | Santa Monica, California, United States | — |
| UPMC Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| Tennessee Cancer Specialists - Biomedical Research | Knoxville, Tennessee, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Millennium Research & Clinical Development | Houston, Texas, United States | — |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | — |
| Institut Jules Bordet - Department of Institut Jules Bordet' | Anderlecht, Belgium | — |
| UZA - Oncology | Edegem, Belgium | — |
| Jessa Ziekenhuis Hospital | Hasselt, Belgium | — |
| Universitair Ziekenhuis Brussel - UZB | Jette, Belgium | — |
| UZ Leuven | Leuven, Belgium | — |
| CHU de Liège - PARENT | Liège, Belgium | — |
+ 42 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05882734